Base de dados : MEDLINE Pesquisa : C04.557.470.035.100 [Categoria DeCS] Referências encontradas : 4053 [refinar] Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 406

ir para página

1 / 4053

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 27845339 [Au] Autor: Kaur S; Smith LM; Patel A; Menning M; Watley DC; Malik SS; Krishn SR; Mallya K; Aithal A; Sasson AR; Johansson SL; Jain M; Singh S; Guha S; Are C; Raimondo M; Hollingsworth MA; Brand RE; Batra SK [Ad] Endereço: Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA. [Ti] Título: A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. [So] Source: Am J Gastroenterol;112(1):172-183, 2017 Jan. [Is] ISSN: 1572-0241 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: OBJECTIVES: Pancreatic cancer (PC) is a lethal malignancy that lacks specific diagnostic markers. The present study explores the diagnostic potential of the most differentially overexpressed secretory mucin MUC5AC alone and in combination with CA19-9 using multi-center training and validation sets. METHODS: The expression of MUC5AC in benign pancreatic pathologies, PC precursor lesions, primary PC tissues and metastatic lesions was evaluated by immunohistochemistry. Circulating MUC5AC levels were measured using sandwich ELISA assay developed in-house, and CA19-9 was measured using radioimmunoassay. A combined training set (n=346) was used to evaluate the diagnostic (n=241) and predictive (n=105, total samples 201 from pre- and post-surgical and chemotherapy set) significance of MUC5AC. Results were further validated with a pre-defined cut-off value using independent sets from the Mayo Clinic (n=94) and the University of Pittsburgh Medical Center (n=321). RESULTS: Tissue expression analyses indicated the de novo expression of MUC5AC in pancreatic intraepithelial precursor lesions 1A (PanIN1A); the expression was maintained through all stages of progression to invasive adenocarcinoma. The median circulating MUC5AC levels in patients with resectable early-stage PC (EPC) (stage 1/2; 67.2 ng/ml, IQR: 23.9-382.1) and unresectable late-stage PC (LPC) (stage 3/4; 389.7 ng/ml, IQR: 87.7-948.6) were significantly higher compared with (P-value ≤0.0001) benign controls (BC) (7.2 ng/ml, IQR: 0.4-26.5) and (P-value ≤0.0001) chronic pancreatitis (CP) controls (8.4 ng/ml, IQR: 1.5-19.2). In the diagnostic training set (n=241), MUC5AC efficiently differentiated EPC from healthy controls (HC) (83%/80% sensitive (SN)/specific (SP)), BC (67%/87% SN/SP), and CP (83%/77% SN/SP). Independent validation sets from the Mayo Clinic and UPMC confirmed the diagnostic potential of MUC5AC to differentiate EPC from BC (68%/73%; 65%/83%) and CP (68%/79%; 65%/72%). Furthermore, MUC5AC and CA19-9 combination significantly improved (p-value < 0.001) the diagnostic accuracy for differentiating resectable cases from controls. CONCLUSIONS: MUC5AC is a valuable diagnostic biomarker, either alone or in combination with CA19-9, to differentiate PC from CP and benign controls. [Mh] Termos MeSH primário: Biomarcadores Tumorais/metabolismo Antígeno CA-19-9/metabolismo Carcinoma Ductal Pancreático/metabolismo Mucina-5AC/metabolismo Neoplasias Pancreáticas/metabolismo [Mh] Termos MeSH secundário: Adenoma de Células das Ilhotas Pancreáticas/metabolismo Carcinoma Ductal Pancreático/diagnóstico Estudos de Casos e Controles Ensaio de Imunoadsorção Enzimática Seres Humanos Imuno-Histoquímica Análise Multivariada Neoplasias Pancreáticas/diagnóstico Pancreatite Crônica/metabolismo Radioimunoensaio Sensibilidade e Especificidade [Pt] Tipo de publicação: JOURNAL ARTICLE; MULTICENTER STUDY [Nm] Nome de substância: 0 (Biomarkers, Tumor); 0 (CA-19-9 Antigen); 0 (MUC5AC protein, human); 0 (Mucin 5AC) [Em] Mês de entrada: 1706 [Cu] Atualização por classe: 170714 [Lr] Data última revisão: 170714 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 161116 [St] Status: MEDLINE [do] DOI: 10.1038/ajg.2016.482

2 / 4053

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 26984080 [Au] Autor: Kobayashi A; Takahashi M; Imai H; Akiyama S; Sugiyama S; Komine K; Saijo K; Takahashi M; Takahashi S; Shirota H; Sato N; Fujishima F; Shuin T; Shimodaira H; Ishioka C [Ad] Endereço: Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Japan. [Ti] Título: Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease. [So] Source: Intern Med;55(6):629-34, 2016. [Is] ISSN: 1349-7235 [Cp] País de publicação: Japan [La] Idioma: eng [Ab] Resumo: von Hippel-Lindau (VHL) disease, caused by germline mutations in the VHL gene, is a hereditary autosomal-dominant disorder which predisposes the individual to various malignant and benign tumors. VHL acts as a tumor suppressor, mainly through the negative regulation of hypoxia-inducible factors. Molecular-targeted drugs against vascular endothelial growth factor-signaling pathways, a target of hypoxia-inducible factors, have recently been introduced into clinical practice for the treatment of patients with sporadic renal cell carcinoma and pancreatic neuroendocrine tumors. However, whether such treatments are effective in patients with VHL disease remains to be elucidated. We herein report a Japanese patient with VHL disease who was successfully treated with sunitinib for approximately 5 years. [Mh] Termos MeSH primário: Adenoma de Células das Ilhotas Pancreáticas/tratamento farmacológico Antineoplásicos/administração & dosagem Carcinoma de Células Renais/tratamento farmacológico Indóis/administração & dosagem Neoplasias Renais/tratamento farmacológico Neoplasias Pancreáticas/tratamento farmacológico Pirróis/administração & dosagem Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores Doença de von Hippel-Lindau/complicações [Mh] Termos MeSH secundário: Adenoma de Células das Ilhotas Pancreáticas/complicações Adenoma de Células das Ilhotas Pancreáticas/diagnóstico Adulto Antineoplásicos/farmacologia Carcinoma de Células Renais/complicações Carcinoma de Células Renais/diagnóstico Esquema de Medicação Evolução Fatal Genes Supressores de Tumor/efeitos dos fármacos Mutação em Linhagem Germinativa/efeitos dos fármacos Seres Humanos Indóis/farmacologia Neoplasias Renais/complicações Neoplasias Renais/diagnóstico Masculino Neoplasias Pancreáticas/complicações Neoplasias Pancreáticas/diagnóstico Pirróis/farmacologia Transdução de Sinais/efeitos dos fármacos Fatores de Tempo [Pt] Tipo de publicação: CASE REPORTS; JOURNAL ARTICLE [Nm] Nome de substância: 0 (Antineoplastic Agents); 0 (Indoles); 0 (Pyrroles); 0 (VEGFA protein, human); 0 (Vascular Endothelial Growth Factor A); V99T50803M (sunitinib) [Em] Mês de entrada: 1610 [Cu] Atualização por classe: 170103 [Lr] Data última revisão: 170103 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160318 [St] Status: MEDLINE [do] DOI: 10.2169/internalmedicine.55.5796

3 / 4053

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 26895682 [Au] Autor: Amin S; Kim MK [Ad] Endereço: Division of Gastroenterology, Department of Medicine Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1069, New York, NY 10029, USA. [Ti] Título: Islet Cell Tumors of the Pancreas. [So] Source: Gastroenterol Clin North Am;45(1):83-100, 2016 Mar. [Is] ISSN: 1558-1942 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: Islet cell tumors of the pancreas, also known as pancreatic neuroendocrine tumors, constitute less than 5% of pancreatic tumors, and 7% of all neuroendocrine tumors. Most are non-functional, and patients often present with metastatic disease. Functional tumors present with distinct clinical syndromes. Accurate staging is critical as surgery is both the cornerstone of treatment, and the only hope for cure. Medical management involves treating the manifestations of hormonal excess, and using somatastatin analogues when appropriate. Systemic chemotherapy, targeted molecular therapy, and peptide receptor radiotherapy may be used for refractory disease in lieu of or as an adjunct to surgery. [Mh] Termos MeSH primário: Adenoma de Células das Ilhotas Pancreáticas/terapia Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico Hormônios/uso terapêutico Neoplasias Hepáticas/terapia Tumores Neuroendócrinos/terapia Neoplasias Pancreáticas/terapia [Mh] Termos MeSH secundário: Adenoma de Células das Ilhotas Pancreáticas/diagnóstico por imagem Adenoma de Células das Ilhotas Pancreáticas/patologia Endossonografia Seres Humanos Neoplasias Hepáticas/secundário Imagem por Ressonância Magnética Terapia de Alvo Molecular Neoplasia Endócrina Múltipla Tipo 1 Tumores Neuroendócrinos/diagnóstico por imagem Tumores Neuroendócrinos/secundário Pancreatectomia Neoplasias Pancreáticas/diagnóstico por imagem Neoplasias Pancreáticas/patologia Pancreaticoduodenectomia Tomografia por Emissão de Pósitrons Cintilografia Receptores de Somatostatina Somatostatina/análogos & derivados Tomografia Computadorizada por Raios X Doença de von Hippel-Lindau [Pt] Tipo de publicação: JOURNAL ARTICLE; REVIEW [Nm] Nome de substância: 0 (Hormones); 0 (Receptors, Somatostatin); 51110-01-1 (Somatostatin) [Em] Mês de entrada: 1612 [Cu] Atualização por classe: 161230 [Lr] Data última revisão: 161230 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160221 [St] Status: MEDLINE

4 / 4053

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 26801953 [Au] Autor: Pérez-Pevida B; Idoate MÁ; Fernández-Landázuri S; Varo N; Escalada J [Ad] Endereço: Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Spain. bppevida@unav.es. [Ti] Título: Hypoglycemic Syndrome without Hyperinsulinemia. A Diagnostic Challenge. [So] Source: Endocr Pathol;27(1):50-4, 2016 Mar. [Is] ISSN: 1559-0097 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: The most common cause of organic fasting hypoglycemia in adults is the presence of an insulin-producing pancreatic adenoma, but when high insulin levels are not found, the differential diagnosis is challenging. Misdiagnosis can lead to an unnecessary pancreatectomy. Insulin concentrations may be low in some cases despite a clinical history suggestive of insulinoma. In these cases, a proinsulinoma should be suspected, although the rarity of this condition requires an extensive workup before reaching a final diagnosis. We describe an unusual case of a 38-year-old man with a severe hypoglycemic syndrome due to a proinsulin-secreting pancreatic adenoma. Insulin was measured by the specific assay and suppressed under the lower detection limit during fasting hypoglycemia. Serum proinsulin and C-peptide levels were abnormally elevated, and further tests revealed an islet cell tumor. The tumor was surgically removed, relieving the fasting hypoglycemia. Histopathological study showed a conventional well-differentiated neuroendocrine tumor with high immunoreactivity against proinsulin and with lesser intensity against insulin. Interestingly, GS-9A8 antibody clone used for immunostaining proinsulin did not cross-react with human insulin or C-peptide, providing an unbiased picture of proinsulin secretion. The resolution of symptoms, the fall of proinsulin concentrations after tumor removal and the histopathology study confirmed the diagnosis of proinsulinoma. [Mh] Termos MeSH primário: Adenoma de Células das Ilhotas Pancreáticas/sangue Hipoglicemia/etiologia Insulina/sangue Neoplasias Pancreáticas/sangue Proinsulina/sangue [Mh] Termos MeSH secundário: Adenoma de Células das Ilhotas Pancreáticas/patologia Adenoma de Células das Ilhotas Pancreáticas/cirurgia Adulto Peptídeo C/análise Peptídeo C/metabolismo Seres Humanos Hiperinsulinismo Masculino Neoplasias Pancreáticas/patologia Neoplasias Pancreáticas/cirurgia Síndrome [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (C-Peptide); 0 (Insulin); 9035-68-1 (Proinsulin) [Em] Mês de entrada: 1611 [Cu] Atualização por classe: 171107 [Lr] Data última revisão: 171107 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160124 [St] Status: MEDLINE [do] DOI: 10.1007/s12022-016-9415-x

5 / 4053

MEDLINE

seleciona para imprimir Fotocópia PubMed Central Texto completo Texto completo

[PMID]: 26661846 [Au] Autor: Jilesen AP; van Eijck CH; in't Hof KH; van Dieren S; Gouma DJ; van Dijkum EJ [Ad] Endereço: Department of Surgery, Academic Medical Center, Meibergdreef 9, P. O. Box 22660, 1105 AZ, Amsterdam, The Netherlands. a.p.jilesen@amc.uva.nl. [Ti] Título: Postoperative Complications, In-Hospital Mortality and 5-Year Survival After Surgical Resection for Patients with a Pancreatic Neuroendocrine Tumor: A Systematic Review. [So] Source: World J Surg;40(3):729-48, 2016 Mar. [Is] ISSN: 1432-2323 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: Studies on postoperative complications and survival in patients with pancreatic neuroendocrine tumors (pNET) are sparse and randomized controlled trials are not available. We reviewed all studies on postoperative complications and survival after resection of pNET. A systematic search was performed in the Cochrane Central Register of Controlled Trials, MEDLINE and EMBASE from 2000-2013. Inclusion criteria were studies of resected pNET, which described postoperative complications separately for each surgical procedure and/or 5-year survival after resection. Prospective and retrospective studies were pooled separately and overall pooled if heterogeneity was below 75%. The random-effect model was used. Overall, 2643 studies were identified and after full-text analysis 62 studies were included. Pancreatic fistula (PF) rate of the prospective studies after tumor enucleation was 45%; PF-rates after distal pancreatectomy, pancreatoduodenectomy, or central pancreatectomy were, respectively, 14-14-58%. Delayed gastric emptying rates were, respectively, 5-5-18-16%. Postoperative hemorrhage rates were, respectively, 6-1-7-4%. In-hospital mortality rates were, respectively, 3-4-6-4%. The 5-year overall survival (OS) and disease-specific survival (DSS) of resected pNET without synchronous resected liver metastases were, respectively, 85-93%. Heterogeneity between included studies on 5-year OS in patients with synchronous resected liver metastases was too high to pool all studies. The 5-year DSS in patients with liver metastases was 80%. Morbidity after pancreatic resection for pNET was mainly caused by PF. Liver resection in patients with liver metastases seems to have a positive effect on DSS. To reduce heterogeneity, ISGPS criteria and uniform patient groups should be used in the analysis of postoperative outcome and survival. [Mh] Termos MeSH primário: Adenoma de Células das Ilhotas Pancreáticas/mortalidade Tumores Neuroendócrinos/mortalidade Pancreatectomia/efeitos adversos Neoplasias Pancreáticas/mortalidade Complicações Pós-Operatórias/epidemiologia [Mh] Termos MeSH secundário: Adenoma de Células das Ilhotas Pancreáticas/cirurgia Saúde Global Mortalidade Hospitalar/tendências Seres Humanos Morbidade/tendências Tumores Neuroendócrinos/cirurgia Neoplasias Pancreáticas/cirurgia [Pt] Tipo de publicação: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW [Em] Mês de entrada: 1609 [Cu] Atualização por classe: 170220 [Lr] Data última revisão: 170220 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 151215 [St] Status: MEDLINE [do] DOI: 10.1007/s00268-015-3328-6

6 / 4053

MEDLINE

seleciona para imprimir Fotocópia PubMed Central Texto completo Texto completo

[PMID]: 26608956 [Au] Autor: Jilesen AP; van Eijck CH; Busch OR; van Gulik TM; Gouma DJ; van Dijkum EJ [Ad] Endereço: Department of Surgery, Academic Medical Center, Meibergdreef 9, PO Box 22660, 1105 AZ, Amsterdam, The Netherlands. a.p.jilesen@amc.uva.nl. [Ti] Título: Postoperative Outcomes of Enucleation and Standard Resections in Patients with a Pancreatic Neuroendocrine Tumor. [So] Source: World J Surg;40(3):715-28, 2016 Mar. [Is] ISSN: 1432-2323 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: BACKGROUND: Either enucleation or more extended resection is performed to treat patients with pancreatic neuroendocrine tumor (pNET). Aim was to analyze the postoperative complications for each operation separately. Furthermore, independent risk factors for complications and incidence of pancreatic insufficiency were analyzed. METHODS: Retrospective all resected patients from two academic hospitals in The Netherlands between 1992 and 2013 were included. Postoperative complications were scored by both ISGPS and Clavien-Dindo criteria. Based on tumor location, operations were compared. Independent risk factors for overall complications were identified. During long-term follow-up, pancreatic insufficiency and recurrent disease were analyzed. RESULTS: Tumor enucleation was performed in 60/205 patients (29%), pancreatoduodenectomy in 65/205 (31%), distal pancreatectomy in 72/205 (35%) and central pancreatectomy in 8/205 (4%) patients. Overall complications after tumor enucleation of the pancreatic head and pancreatoduodenectomy were comparable, 24/35 (69%) versus 52/65 (80%). The same was found after tumor enucleation and resection of the pancreatic tail (36 vs.58%). Number of re-interventions and readmissions were comparable between all operations. After pancreatoduodenectomy, 33/65 patients had lymph node metastasis and in patients with tumor size ≤2 cm, 55% had lymph node metastasis. Tumor in the head and BMI ≥25 kg/m(2) were independent risk factors for complications after enucleation. During follow-up, incidence of exocrine and endocrine insufficiency was significant higher after pancreatoduodenectomy (resp. 55 and 19%) compared to the tumor enucleation and distal pancreatectomy (resp. 5 and 7% vs. 8 and 13%). After tumor enucleation 19% developed recurrent disease. CONCLUSION: Since the complication rate, need for re-interventions and readmissions were comparable for all resections, tumor enucleation may be regarded as high risk. Appropriate operation should be based on tumor size, location, and functional status of the pNET. [Mh] Termos MeSH primário: Adenoma de Células das Ilhotas Pancreáticas/cirurgia Pâncreas/cirurgia Pancreatectomia/efeitos adversos Neoplasias Pancreáticas/cirurgia Complicações Pós-Operatórias/epidemiologia [Mh] Termos MeSH secundário: Adenoma de Células das Ilhotas Pancreáticas/mortalidade Feminino Seres Humanos Masculino Meia-Idade Recidiva Local de Neoplasia/epidemiologia Países Baixos/epidemiologia Neoplasias Pancreáticas/mortalidade Estudos Retrospectivos Fatores de Risco Fatores de Tempo Resultado do Tratamento [Pt] Tipo de publicação: JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T [Em] Mês de entrada: 1609 [Cu] Atualização por classe: 170220 [Lr] Data última revisão: 170220 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 151127 [St] Status: MEDLINE [do] DOI: 10.1007/s00268-015-3341-9

7 / 4053

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 24428588 [Au] Autor: Finotello R; Ressel L; Arvigo M; Baroni G; Marchetti V; Romanelli G; Burrow R; Mignacca D; Blackwood L [Ad] Endereço: Small Animal Teaching Hospital, School of Veterinary Sciences, University of Liverpool, Liverpool, UK. [Ti] Título: Canine pancreatic islet cell tumours secreting insulin-like growth factor type 2: a rare entity. [So] Source: Vet Comp Oncol;14(2):170-80, 2016 Jun. [Is] ISSN: 1476-5829 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: Insulin-like growth factor type II (IGF-II) is the main cause of non-islet cell tumour hypoglycaemia (NICTH) and insulin is thought to be the only factor causing hypoglycaemia in insulinomas. However, two case reports of pancreatic neuroendocrine tumours (PNETs) producing IGF-II have been previously published: a human and a canine patient. In this study, we investigated clinical, histopathological, immunohistochemical and ultrastructural features, and biological behaviour of canine pancreatic IGF-II-omas, a subgroup of PNETs that has not been previously characterized. Case records of 58 dogs with confirmed PNETs and hypoglycaemia were reviewed: six patients were affected by IGF-II-omas. Surgery was performed in all cases and two dogs had metastases. Four patients remained alive and in remission at 370, 440, 560 and 890 days post-diagnosis; two died of non-tumour-related causes. IGF-II-omas can be differentiated from insulinomas through hypoinsulinaemia, IGF-II positive and insulin negative immunostaining. The prevalence of this neoplasia is low, accounting for just 6% of PNETs. [Mh] Termos MeSH primário: Adenoma de Células das Ilhotas Pancreáticas/veterinária Doenças do Cão/metabolismo Fator de Crescimento Insulin-Like II/metabolismo Neoplasias Pancreáticas/veterinária [Mh] Termos MeSH secundário: Adenoma de Células das Ilhotas Pancreáticas/genética Adenoma de Células das Ilhotas Pancreáticas/metabolismo Animais Doenças do Cão/genética Cães Feminino Regulação Neoplásica da Expressão Gênica/fisiologia Fator de Crescimento Insulin-Like II/genética Masculino Neoplasias Pancreáticas/genética Neoplasias Pancreáticas/metabolismo Estudos Retrospectivos [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 67763-97-7 (Insulin-Like Growth Factor II) [Em] Mês de entrada: 1704 [Cu] Atualização por classe: 170413 [Lr] Data última revisão: 170413 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 140117 [St] Status: MEDLINE [do] DOI: 10.1111/vco.12085

8 / 4053

MEDLINE

seleciona para imprimir Fotocópia

[PMID]: 26897971 [Au] Autor: Fu W; Li J; Wen J; Lin G; Wei Z; Deng J; Li Q; Lei Z [Ti] Título: Management of Islet Cell Tumours: A Single Hospital Experience. [So] Source: Hepatogastroenterology;62(139):773-6, 2015 May. [Is] ISSN: 0172-6390 [Cp] País de publicação: Greece [La] Idioma: eng [Ab] Resumo: BACKGROUND/AIMS: Islet cell tumours (ICTs) are uncommon tumours in clinical practice. Surgical resection is the treatment of choice for ICTs, but localisation of these lesions can be challenging. The aim of this study was to analyse the clinical diagnosis and treatment for ICTs. METHODS: Thirty-one patients with ICTs who were diagnosed and who underwent surgical treatment in the affiliate hospital of Luzhou Medical College from 1 January 2000 to 31 July 2013 were enrolled. The clinical data of these patients were retrospectively reviewed. RESULTS: Among 31 patients (6 males, 25 females), 15 cases (48.39%) had non-functional ICTs and 16 (51.61%) cases were insulinoma. The mean age of patients with non-functional ICTs was 42.73 ± 12.34 years and of those with insulinoma was 48.88 ± 13 years. Non-functional ICTs had a non-specific presentation. Insulinoma makes different clinical presentations mostly with symptoms of hypoglycaemia. CONCLUSIONS: Preoperative and/or intra-operative localisation is needed for ICTs; CT scan or MRI is used routinely as the first choice. If the lesion is very small, DSA is also good for localisation before operation. IOUS is a reliable technique in exactly localising insulinoma. ICTs are considered to be cured with successful surgical removal. [Mh] Termos MeSH primário: Adenoma de Células das Ilhotas Pancreáticas/diagnóstico Adenoma de Células das Ilhotas Pancreáticas/cirurgia Diagnóstico por Imagem/métodos Insulinoma/diagnóstico Insulinoma/cirurgia Pancreatectomia Neoplasias Pancreáticas/diagnóstico Neoplasias Pancreáticas/cirurgia [Mh] Termos MeSH secundário: Adenoma de Células das Ilhotas Pancreáticas/patologia Adulto Angiografia Digital China Feminino Seres Humanos Insulinoma/patologia Imagem por Ressonância Magnética Masculino Meia-Idade Imagem Multimodal Pancreatectomia/efeitos adversos Neoplasias Pancreáticas/patologia Valor Preditivo dos Testes Reprodutibilidade dos Testes Estudos Retrospectivos Tomografia Computadorizada por Raios X Resultado do Tratamento Carga Tumoral [Pt] Tipo de publicação: JOURNAL ARTICLE [Em] Mês de entrada: 1603 [Cu] Atualização por classe: 160222 [Lr] Data última revisão: 160222 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160223 [St] Status: MEDLINE

9 / 4053

MEDLINE

seleciona para imprimir Fotocópia

[PMID]: 26897961 [Au] Autor: Fu W; Li J; Wen J; Gao L; Zeng W; Deng J; Li Q; Lei Z [Ti] Título: Management of Islet Cell Tumours: A Single Hospital Experience. [So] Source: Hepatogastroenterology;62(139):723-6, 2015 May. [Is] ISSN: 0172-6390 [Cp] País de publicação: Greece [La] Idioma: eng [Ab] Resumo: BACKGROUND/AIMS: Islet cell tumours (ICTs) are uncommon tumours in clinical practice. Surgical resection is the treatment of choice for ICTs, but localisation of these lesions can be challenging. The aim of this study was to analyse the clinical diagnosis and treatment for ICTs. METHODOLOGY: Thirty-one patients with ICTs who were diagnosed and who underwent surgical treatment in the affiliate hospital of Luzhou Medical College from 1 January 2000 to 31 July 2013 were enrolled. The clinical data of these patients were retrospectively reviewed. RESULTS: Among 31 patients (6 males, 25 females), 15 cases (48.39%) had non-functional ICTs and 16 (51.61%) cases were insulinoma: The mean age of patients with non-functional ICTs was 42.73 ± 12.34 years and of those with insulinoma was 48.88 ± 13 years. Non-functional ICTs had a non-specific presentation. Insulinoma makes different clinical presentations mostly with symptoms of hypoglycaemia. CONCLUSIONS: Preoperative and/or intra-operative localisation is needed for ICTs; CT scan or MRI is used routinely as the first choice. If the lesion is very small, DSA is also good for localisation before operation. IOUS is a reliable technique in exactly localising insulinoma. ICTs are considered to be cured with successful surgical removal. [Mh] Termos MeSH primário: Adenoma de Células das Ilhotas Pancreáticas/diagnóstico Adenoma de Células das Ilhotas Pancreáticas/cirurgia Diagnóstico por Imagem/métodos Insulinoma/diagnóstico Insulinoma/cirurgia Pancreatectomia Neoplasias Pancreáticas/diagnóstico Neoplasias Pancreáticas/cirurgia [Mh] Termos MeSH secundário: Adenoma de Células das Ilhotas Pancreáticas/patologia Adulto Idoso Angiografia Digital China Feminino Seres Humanos Insulinoma/patologia Imagem por Ressonância Magnética Masculino Meia-Idade Imagem Multimodal Pancreatectomia/efeitos adversos Neoplasias Pancreáticas/patologia Valor Preditivo dos Testes Reprodutibilidade dos Testes Estudos Retrospectivos Tomografia Computadorizada por Raios X Resultado do Tratamento Carga Tumoral Adulto Jovem [Pt] Tipo de publicação: JOURNAL ARTICLE [Em] Mês de entrada: 1603 [Cu] Atualização por classe: 160222 [Lr] Data última revisão: 160222 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160223 [St] Status: MEDLINE

10 / 4053

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 25689919 [Au] Autor: Grozinsky-Glasberg S; Mazeh H; Gross DJ [Ad] Endereço: Neuroendocrine Tumor Unit, Endocrinology and Metabolism Service, Department of Medicine, Hadassah-Hebrew University Medical Center, P.O.B. 12000, Jerusalem, 91120, Israel. simonag@hadassah.org.il. [Ti] Título: Clinical features of pancreatic neuroendocrine tumors. [So] Source: J Hepatobiliary Pancreat Sci;22(8):578-85, 2015 Aug. [Is] ISSN: 1868-6982 [Cp] País de publicação: Japan [La] Idioma: eng [Ab] Resumo: Pancreatic neuroendocrine tumors (PNETs), also known as islet cell tumors, are rare neoplasms that arise in the endocrine tissues of the pancreas. Most of pancreatic NETs (50-75%) are nonfunctioning (not associated with a hormonal clinical syndrome); however, in up to one third they can secrete a variety of peptide hormones, including insulin, gastrin, glucagon, vasoactive intestinal peptide, somatostatin etc., resulting in rare but unique clinical syndromes. In this article, the clinical features of the different types of PNETs will be reviewed. Other aspects of the management of these tumors (surgery, treatment of advanced disease, tumor localization) are not dealt with here, as they are covered by other papers in this volume. [Mh] Termos MeSH primário: Tumores Neuroendócrinos Neoplasias Pancreáticas [Mh] Termos MeSH secundário: Adenoma de Células das Ilhotas Pancreáticas Seres Humanos Proteoglicanas Somatostatinoma Vipoma Síndrome de Zollinger-Ellison [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Proteoglycans); 0 (glucidamine) [Em] Mês de entrada: 1605 [Cu] Atualização por classe: 160511 [Lr] Data última revisão: 160511 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 150219 [St] Status: MEDLINE [do] DOI: 10.1002/jhbp.226

---

página 1 de 406

ir para página

Refinar a pesquisa

Base de dados : MEDLINE

Formulário avançado

		Pesquisar	no campo
1			PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2
2	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2
3	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde